BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24890873)

  • 1. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17.
    Verver E; Pecci A; De Rocco D; Ryhänen S; Barozzi S; Kunst H; Topsakal V; Savoia A
    Clin Genet; 2015 Jul; 88(1):85-9. PubMed ID: 24890873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder.
    Wasano K; Matsunaga T; Ogawa K; Kunishima S
    Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3547-3552. PubMed ID: 26942920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
    Zaninetti C; De Rocco D; Giangregorio T; Bozzi V; Demeter J; Leoni P; Noris P; Ryhänen S; Barozzi S; Pecci A; Savoia A
    Hamostaseologie; 2019 Feb; 39(1):87-94. PubMed ID: 29996171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
    Pecci A; Klersy C; Gresele P; Lee KJ; De Rocco D; Bozzi V; Russo G; Heller PG; Loffredo G; Ballmaier M; Fabris F; Beggiato E; Kahr WH; Pujol-Moix N; Platokouki H; Van Geet C; Noris P; Yerram P; Hermans C; Gerber B; Economou M; De Groot M; Zieger B; De Candia E; Fraticelli V; Kersseboom R; Piccoli GB; Zimmermann S; Fierro T; Glembotsky AC; Vianello F; Zaninetti C; Nicchia E; Güthner C; Baronci C; Seri M; Knight PJ; Balduini CL; Savoia A
    Hum Mutat; 2014 Feb; 35(2):236-47. PubMed ID: 24186861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A; Panza E; Pujol-Moix N; Klersy C; Di Bari F; Bozzi V; Gresele P; Lethagen S; Fabris F; Dufour C; Granata A; Doubek M; Pecoraro C; Koivisto PA; Heller PG; Iolascon A; Alvisi P; Schwabe D; De Candia E; Rocca B; Russo U; Ramenghi U; Noris P; Seri M; Balduini CL; Savoia A
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
    Sun XH; Wang ZY; Yang HY; Cao LJ; Su J; Yu ZQ; Bai X; Ruan CG
    Acta Haematol; 2013; 129(2):106-13. PubMed ID: 23207509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of
    Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
    Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
    [No Abstract]   [Full Text] [Related]  

  • 9. Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder.
    Savoia A; De Rocco D; Panza E; Bozzi V; Scandellari R; Loffredo G; Mumford A; Heller PG; Noris P; De Groot MR; Giani M; Freddi P; Scognamiglio F; Riondino S; Pujol-Moix N; Fabris F; Seri M; Balduini CL; Pecci A
    Thromb Haemost; 2010 Apr; 103(4):826-32. PubMed ID: 20174760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype Correlation of the p.R1165C Mutation in the MYH9 Disorder: Report of a Japanese Pedigree.
    Okano S; Takase M; Iseki K; Toriumi N; Kaneda M; Kunishima S
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e352-5. PubMed ID: 26056797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.
    De Rocco D; Zieger B; Platokouki H; Heller PG; Pastore A; Bottega R; Noris P; Barozzi S; Glembotsky AC; Pergantou H; Balduini CL; Savoia A; Pecci A
    Eur J Med Genet; 2013 Jan; 56(1):7-12. PubMed ID: 23123319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
    Pecci A; Canobbio I; Balduini A; Stefanini L; Cisterna B; Marseglia C; Noris P; Savoia A; Balduini CL; Torti M
    Hum Mol Genet; 2005 Nov; 14(21):3169-78. PubMed ID: 16162639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial cases with MYH9 disorders caused by MYH9 S96L mutation.
    Murayama S; Akiyama M; Namba H; Wada Y; Ida H; Kunishima S
    Pediatr Int; 2013 Feb; 55(1):102-4. PubMed ID: 23409987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of hearing loss in a mouse model for DFNA17 and MYH9-related disease: the use of public gene-targeted ES cell resources.
    Parker LL; Gao J; Zuo J
    Brain Res; 2006 May; 1091(1):235-42. PubMed ID: 16630581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
    Arif AR; Zhao M; Chen W; Xue M; Luo S; Wang Y
    Platelets; 2022 Nov; 33(8):1307-1311. PubMed ID: 35791514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYH9 disorder: Identification and a novel mutation in patients with macrothrombocytopenia.
    Natesirinilkul R; Sosothikul D; Komwilaisak P; Pongtanakul B; Narkbunnum N; Yudhasompop N; Mekjarusgool P; Niparuck P; Boonyawat K; Kunishima S; Sirachainan N;
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29055. PubMed ID: 33855781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hereditary sensorineural hearing impairment and macrothrombocytopenia: a rare MYH9 gene mutation].
    Böttcher A; Knecht R; Busch CJ; Lörincz BB; Dalchow CV
    HNO; 2013 Feb; 61(2):159-60, 162-5. PubMed ID: 23223919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel de novo MYH9 mutation in MYH9-related disease: A case report and review of literature.
    Ai Q; Zhao L; Yin J; Jiang L; Jin Q; Hu X; Chen S
    Medicine (Baltimore); 2020 Jan; 99(4):e18887. PubMed ID: 31977897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal manifestations of patients with MYH9-related disorders.
    Han KH; Lee H; Kang HG; Moon KC; Lee JH; Park YS; Ha IS; Ahn HS; Choi Y; Cheong HI
    Pediatr Nephrol; 2011 Apr; 26(4):549-55. PubMed ID: 21210153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.